In a recent whole blood transcriptomic study of 41 severe asthma patients, in which gene expression levels in peripheral blood were compared at baseline and after four months of treatment with benralizumab [15], significant reductions in the expression of genes associated with eosinophilic inflammatory responses, such as PTGDR2, ALOX15, IL5RA, SMPD3, CLC, HRH4, CYSLTR2, and RAB44, were observed. Here, RAB44 is linked to asthma.